

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau


(43) International Publication Date
10 November 2022 (10.11.2022)



(10) International Publication Number
WO 2022/236047 A1

- (51) **International Patent Classification:**
A61P 37/00 (2006.01) *C07K 16/28* (2006.01)
- (21) **International Application Number:**
PCT/US2022/028063
- (22) **International Filing Date:**
06 May 2022 (06.05.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/185,613 07 May 2021 (07.05.2021) US
63/303,655 27 January 2022 (27.01.2022) US
- (71) **Applicant: VIELA BIO, INC.** [US/US]; One MedImmune Way, First Floor, Area Two, Gaithersburg, Maryland 20878 (US).
- (72) **Inventors: KATZ, Eliezer;** c/o Viela Bio, Inc., One MedImmune Way, Gaithersburg, Maryland 20878 (US). **RATCHFORD, John N.;** c/o Viela Bio, Inc., One MedImmune Way, Gaithersburg, Maryland 20878 (US). **ABUHSIRA, Liron;** c/o Viela Bio, Inc., One MedImmune Way, Gaithersburg, Maryland 20878 (US).
- (74) **Agent: FREHE, Claudia J. et al.;** COOLEY LLP, 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) **Title:** USE OF AN ANTI-CD19 ANTIBODY TO TREAT MYASTHENIA GRAVIS



AChR-Ab+ = positive for antibodies against the acetylcholine receptor; MuSK-Ab+ = positive for antibodies against muscle-specific kinase. n = number of subjects represent upper estimated limit and may be reduced based on enrollment of subjects in Japan.

FIG. 1

(57) **Abstract:** Methods for using an anti-CD19 antibody to treat autoimmune disease are disclosed herein. In particular, the disclosure provides for the use of Inebilizumab, a humanized, affinity-optimized, afucosylated IgG1 kappa monoclonal antibody to treat myasthenia gravis.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*